Clovis Oncology, Inc.
5500 Flatiron Parkway, Suite 100
Boulder, CO 80301
December 27, 2019
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549
Attn: | Mr. Chris Edwards |
Re: Clovis Oncology, Inc.—Request for Acceleration
Registration Statement on Form S-3
(File No. 333-235536)
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Clovis Oncology, Inc. (the “Registrant”) hereby respectfully requests that the effectiveness of the above-captioned Registration Statement on Form S-3 (the “Registration Statement”) be accelerated to December 30, 2019 at 9:00 a.m. Eastern Time or as soon as practicable thereafter.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Sincerely,
Clovis Oncology, Inc.
By: | /s/ Paul Gross |
Name: Paul Gross | ||
Title: Executive Vice President, General Counsel and Chief Compliance Officer |
cc: | Thomas Mark, Esq., Willkie Farr & Gallagher LLP |